| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of General Medicine [E. H., T. Y.], First Department of Surgery [N. T., Y. I., Y. M., T. K., Y. M.], and Second Department of Internal Medicine [K. H.], Hiroshima University School of Medicine, 1-2-3, Kasumi, Minami-ku, Hiroshima 734, Japan, and University of Texas Southwestern Medical Center at Dallas, Department of Cell Biology and Neuroscience, Dallas, Texas 75235-9039 [M. A. P., J. W. S.]
Although many genetic alterations have been reported in gastric cancer, it is not known whether all gastric tumors are capable of indefinite proliferative potential, e.g., immortality. The expression of telomerase and stabilization of telomeres are concomitant with the attainment of immortality in tumor cells; thus, the measurement of telomerase activity in clinically obtained tumor samples may provide important information useful both as a diagnostic marker to detect immortal cancer cells in clinical materials and as a prognostic indicator of patient outcome. Telomerase activity was analyzed in 66 primary gastric cancers with the use of a PCR-based assay. The majority of tumors (85%) displayed telomerase activity, but telomerase was undetectable in 10 tumors (15%), 8 of which were early stage tumors. Most of the tumors with telomerase activity were large and of advanced stages, including metastases. Survival rate of patients of tumors with detectable telomerase activity was significantly shorter than that of those without telomerase activity. Alterations of telomere length (reduced/elongated terminal restriction fragments) were detected in 14 of 66 (21%) gastric cancers, and all 14 had telomerase activity. Cellular DNA contents revealed that all 22 aneuploid tumors had detectable telomerase activity. The present results indicate that telomerase activation may be required as a critical step in the multigenetic process of tumorigenesis, and that telomerase is frequently but not always activated as a late event in gastric cancer progression.
1 This work was supported by a Grant-in-Aid from Japanese Ministry of Education, Science and Culture in Japan.
2 To whom requests for reprints should be addressed.
Received 4/11/95. Accepted 6/16/95.
This article has been cited by other articles:
|
|
 |
|
  T. MATSUO, S. SHIMOSE, T. KUBO, J. FUJIMORI, Y. YASUNAGA, and M. OCHI Telomeres and Telomerase in Sarcomas Anticancer Res, October 1, 2009; 29(10): 3833 - 3836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsuo, J. W. Shay, W. E. Wright, E. Hiyama, S. Shimose, T. Kubo, T. Sugita, Y. Yasunaga, and M. Ochi Telomere-Maintenance Mechanisms in Soft-Tissue Malignant Fibrous Histiocytomas J. Bone Joint Surg. Am., April 1, 2009; 91(4): 928 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, Z. Hu, J. Liang, Z. Wang, J. Tang, S. Wang, X. Wang, J. Qin, X. Wang, and H. Shen A tandem repeat of human telomerase reverse transcriptase (hTERT) and risk of breast cancer development and metastasis in Chinese women Carcinogenesis, June 1, 2008; 29(6): 1197 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-L. Wu, C. Dudognon, E. Nguyen, J. Hillion, F. Pendino, I. Tarkanyi, J. Aradi, M. Lanotte, J.-H. Tong, G.-Q. Chen, et al. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths J. Cell Sci., July 1, 2006; 119(13): 2797 - 2806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, Q. Wei, L.-E Wang, K. D. Aldape, Y. Cao, M. F. Okcu, K. R. Hess, R. El-Zein, M. R. Gilbert, S. Y. Woo, et al. Survival Prediction in Patients With Glioblastoma Multiforme by Human Telomerase Genetic Variation J. Clin. Oncol., April 1, 2006; 24(10): 1627 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Dome, C. A. Bockhold, S. M. Li, S. D. Baker, D. M. Green, E. J. Perlman, D. A. Hill, and N. E. Breslow High Telomerase RNA Expression Level Is an Adverse Prognostic Factor for Favorable-Histology Wilms' Tumor J. Clin. Oncol., December 20, 2005; 23(36): 9138 - 9145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li, J. Crothers, C. M. Haqq, and E. H. Blackburn Cellular and Gene Expression Responses Involved in the Rapid Growth Inhibition of Human Cancer Cells by RNA Interference-mediated Depletion of Telomerase RNA J. Biol. Chem., June 24, 2005; 280(25): 23709 - 23717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ohali, S. Avigad, I.J. Cohen, I. Meller, Y. Kollender, J. Issakov, I. Gelernter, Y. Goshen, I. Yaniv, and R. Zaizov Association Between Telomerase Activity and Outcome in Patients With Nonmetastatic Ewing Family of Tumors J. Clin. Oncol., October 15, 2003; 21(20): 3836 - 3843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S K Mohanty and P Dey Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review Postgrad. Med. J., October 1, 2003; 79(936): 569 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hernandez, F. Garcia-Pons, Y. C. Lone, H. Firat, J. D. Schmidt, P. Langlade-Demoyen, and M. Zanetti Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells PNAS, September 17, 2002; 99(19): 12275 - 12280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wang, J.-C. Soria, B. L. Kemp, D. D. Liu, L. Mao, and F. R. Khuri hTERT Expression Is a Prognostic Factor of Survival in Patients with Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., September 1, 2002; 8(9): 2883 - 2889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Lee, S. C. Abraham, H.-S. Kim, J.-H. Nam, C. Choi, M.-C. Lee, C.-S. Park, S.-W. Juhng, A. Rashid, S. R. Hamilton, et al. Inverse Relationship between APC Gene Mutation in Gastric Adenomas and Development of Adenocarcinoma Am. J. Pathol., August 1, 2002; 161(2): 611 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Lin, S. Lim, M. A. Viani, M. Sapp, and M. S. Lim Down-Regulation of Telomerase Activity in Malignant Lymphomas by Radiation and Chemotherapeutic Agents Am. J. Pathol., August 1, 2001; 159(2): 711 - 719. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Zhang, M. Dong, X. Teng, and T. Chen Quantitative Assay of Telomerase Activity in Head and Neck Squamous Cell Carcinoma and Other Tissues Arch Otolaryngol Head Neck Surg, May 1, 2001; 127(5): 581 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hamet, N. Thorin-Trescases, P. Moreau, P. Dumas, B.-S. Tea, D. deBlois, V. Kren, M. Pravenec, J. Kunes, Y. Sun, et al. Workshop: Excess Growth and Apoptosis : Is Hypertension a Case of Accelerated Aging of Cardiovascular Cells? Hypertension, February 1, 2001; 37(2): 760 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takubo, K.-I. Nakamura, N. Izumiyama, E. Furugori, M. Sawabe, T. Arai, Y. Esaki, K.-I. Mafune, M. Kammori, M. Fujiwara, et al. Telomere Shortening With Aging in Human Liver J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2000; 55(11): 533B - 536. [Abstract] [Full Text]
|
|
|
|
|
|
N. Tatsumoto, E. Hiyama, Y. Murakami, Y. Imamura, J. W. Shay, Y. Matsuura, and T. Yokoyama High Telomerase Activity Is an Independent Prognostic Indicator of Poor Outcome in Colorectal Cancer Clin. Cancer Res., July 1, 2000; 6(7): 2696 - 2701. [Abstract] [Full Text]
|
|
|
|
|
|
P. Rudolph, C. Schubert, S. Tamm, K. Heidorn, A. Hauschild, I. Michalska, S. Majewski, G. Krupp, S. Jablonska, and R. Parwaresch Telomerase Activity in Melanocytic Lesions : A Potential Marker of Tumor Biology Am. J. Pathol., April 1, 2000; 156(4): 1425 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Heine, S. E Coupland, S. Kneiff, G. Demel, N. Bornfeld, M. Hummel, and H. Stein Telomerase expression in uveal melanoma Br J Ophthalmol, February 1, 2000; 84(2): 217 - 223. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Mannelli, S. Gelmini, G. Arnaldi, L. Becherini, D. Bemporad, C. Crescioli, M. Pazzagli, F. Mantero, M. Serio, and C. Orlando Telomerase Activity Is Significantly Enhanced in Malignant Adrenocortical Tumors in Comparison to Benign Adrenocortical Adenomas J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 468 - 470. [Abstract] [Full Text]
|
|
|
|
|
|
L. A. Carey, N. W. Kim, S. Goodman, J. Marks, G. Henderson, C. B. Umbricht, J. S. Dome, W. Dooley, S. R. Amshey, and S. Sukumar Telomerase Activity and Prognosis in Primary Breast Cancers J. Clin. Oncol., October 1, 1999; 17(10): 3075 - 3081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Dome, S. Chung, T. Bergemann, C. B. Umbricht, M. Saji, L. A. Carey, P. E. Grundy, E. J. Perlman, N. E. Breslow, and S. Sukumar High Telomerase Reverse Transcriptase (hTERT) Messenger RNA Level Correlates with Tumor Recurrence in Patients with Favorable Histology Wilms' Tumor Cancer Res., September 1, 1999; 59(17): 4301 - 4307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tangkijvanich, D. Tresukosol, P. Sampatanukul, S. Sakdikul, N. Voravud, V. Mahachai, and A. Mutirangura Telomerase Assay for Differentiating between Malignancy-related and Nonmalignant Ascites Clin. Cancer Res., September 1, 1999; 5(9): 2470 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Marchetti, G. Bertacca, F. Buttitta, A. Chella, G. Quattrocolo, C. A. Angeletti, and G. Bevilacqua Telomerase Activity as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., August 1, 1999; 5(8): 2077 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Yan, J.-M. Coindre, J. Benhattar, F. T. Bosman, and L. Guillou Telomerase Activity and Human Telomerase Reverse Transcriptase mRNA Expression in Soft Tissue Tumors: Correlation with Grade, Histology, and Proliferative Activity Cancer Res., July 1, 1999; 59(13): 3166 - 3170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gong, R. Mera, J. C. Bravo, B. Ruiz, R. Diaz-Escamilla, E. T. H. Fontham, P. Correa, and J. D. Hunt KRAS Mutations Predict Progression of Preneoplastic Gastric Lesions Cancer Epidemiol. Biomarkers Prev., February 1, 1999; 8(2): 167 - 171. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Yajima, A. Yagihashi, H. Kameshima, D. Kobayashi, D. Furuya, K. Hirata, and N. Watanabe Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system Clin. Chem., December 1, 1998; 44(12): 2441 - 2445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kondo, Y. Tanaka, Y. Kondo, M. Hitomi, G. H. Barnett, Y. Ishizaka, J. Liu, T. Haqqi, A. Nishiyama, B. Villeponteau, et al. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation FASEB J, July 1, 1998; 12(10): 801 - 811. [Abstract] [Full Text]
|
|
|
|
|
|
R. Dahse, W. Fiedler, and G. Ernst Telomeres and telomerase: biological and clinical importance Clin. Chem., May 1, 1997; 43(5): 708 - 714. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
